Option chain shows key data for Jaguar Health's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Jaguar Health.

Jaguar Health (NASDAQ:JAGX) Stock, Option Chain

Jaguar Health

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

News

JAGX

Jaguar Health shares are trading lower by 15.4% during Tuesday&#39;s session. The company reported worse-than-expected second-quarter results.

Why Jaguar Health (JAGX) Stock Is Down 15%

Why Does Coca-Cola Taste Different In Other Countries?

Earnings

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ADIL

AZTR

CLRB

FEIM

RNAZ

Gold Moves Higher; Coca-Cola Increases FY24 Forecast

xr:d:DAFp1nJl8vk:2,j:4184241900145690738,t:23072714

AEVA

AROC

ATPC

CGBS

CMAX

CMCSA

DRMA

EFSH

FLYE

FTEL

ICLK

KNSA

MEDP

MESO

MIRA

MLSS

MMYT

MSCI

NCPL

NUKK

NXPI

PCAR

PSIG

SLNA

SLRX

SMFL

SOAR

SPOT

STAF

TUSK

WBTN

XCUR

ZION

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Jaguar Health Inc

Jaguar Health's  Napo Pharmaceuticals Announces FDA Orphan Drug Designation For Crofelemer

Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3 <a href="https://clinicaltrials.gov/study/NCT04538625">OnTarget</a> trial evaluating crofelemer for prophylaxis of CTD
The majority of patients in the OnTarget placebo group on abemaciclib and pertuzumab-based therapies required dose reduction or elimination
SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2024 / <a href="https://pr.report/4u8b">Jaguar Health, Inc.</a> <a href="https://pr.report/4yse">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar") family company <a href="https://pr.report/4u8d">Napo Pharmaceuticals</a> ("Napo") today provided an overview of the data from the poster presentation conducted yesterday, December 11, 2024, at the <a href="https://pr.report/4u8e">San Antonio Breast Cancer Symposium</a> (SABCS) about the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the Phase 3 <a href="https://pr.report/4u8f">OnTarget</a> trial, which indicates that crofelemer achieved statistically significant results in this subgroup. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adults with solid tumors receiving targeted therapy with or without standard chemotherapy.

Biotech

General

Jaguar Health's Napo Pharmaceuticals Reports Crofelemer Shows Statistically Significant Results In Phase 3 OnTarget Trial For Breast Cancer Patients

U.S. Investigator-Initiated Trial To Evaluate Efficacy And Safety Of Jaguar Health's Crofelemer For Short Bowel Syndrome With Intestinal Failure Begins

<a href="https://www.canalevia.com/">Canalevia&#xAE;-CA1</a> is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree
Crofelemer, the active ingredient in Canalevia CA-1, is the subject of Jaguar's recently conducted Phase 3 <a href="https://clinicaltrials.gov/study/NCT04538625">OnTarget</a> trial in humans for cancer therapy-related diarrhea
SAN FRANCISCO, CA / ACCESSWIRE / December 5, 2024 / <a href="https://pr.report/4r5r">Jaguar Health, Inc.</a><a href="https://pr.report/4r6c">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) today announced that an article about <a href="https://pr.report/4r5s">Canalevia-CA1</a> (crofelemer delayed-release tablets), Jaguar's prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, has been published in PetVet Magazine and can be viewed by clicking <a href="https://pr.report/4r5t">here</a>.
Canalevia-CA1 is conditionally approved by the U.S. Food and Drug Administration for the treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any approval from the FDA.

Jaguar Health AnnouncesThat An Article About Canalevia-CA1 (Crofelemer Delayed-Release Tablets), Jaguar's Prescription Drug For The Treatment Of Chemotherapy-Induced Diarrhea In Dogs, Has Been Published In PetVet Magazine

Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(2.37) by 55.7 percent. The company reported quarterly sales of $3.11 million which missed the analyst consensus estimate of $3.94 million by 21.05 percent. This is a 10.52 percent increase over sales of $2.81 million the same period last year.

Jaguar Health Q3 2024 GAAP EPS $(1.05) Beats $(2.37) Estimate, Sales $3.11M Miss $3.94M Estimate

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-11-13. Here's what investors need to know before the announcement.
Analysts estimate that Jaguar Health will report an earnings per share (EPS) of $-2.37. 
Anticipation surrounds Jaguar Health's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
The company's EPS missed by $2.93 in the last quarter, leading to a 0.0% drop in the share price on the following day.

<a href="https://www.benzinga.com/quote/JAGX/earnings">To track all earnings releases for Jaguar Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring Jaguar Health's Earnings Expectations

Jaguar Health Announces Significant Results For Crofelemer In Preventing Cancer Therapy-Related Diarrhea In Breast Cancer Patients; Findings To Be Presented At San Antonio Breast Cancer Symposium

Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair In The U.S., Targeting Painful Chemo-Related Mouth Inflammation

Study Evaluates Incidence, Severity, And Management Of Diarrhea In 75 Breast Cancer Patients Using Targeted Therapies With Or Without Chemotherapy Based On Patient-Reported Outcomes

Jaguar Health Submits Late-Breaking Abstract For Study On Impact Of Diarrhea From Cancer Therapies In Breast Cancer Patients Receiving Placebo During OnTarget Phase 3 Trial

Jaguar Health Announces Recently Completed Analysis Of Prespecified Subgroup Of Adult Patients With Breast Cancer For Phase 3 OnTarget Trial Indicate Crofelemer Achieved Statistical Significance In The Subgroup

Jaguar Supports Proof-Of-Concept Studies For Rare Disease Indications With Results Expected By End Of 2024 And 2025

Jaguar Health Announces New Patent Issued In Hong Kong For Napo Pharmaceuticals' Crofelemer In Treating Short Bowel Syndrome And Related Conditions

Jaguar Health Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares are trading lower by 10% to $1.08 during Tuesday&#8217;s session after the company reported worse-than-expected <a href="https://www.benzinga.com/pressreleases/24/08/ac40335398/jaguar-health-reports-second-quarter-2024-financial-results">second-quarter results</a>.
<h2 class="wp-block-heading">What Happened?</h2>
Jaguar Health posted a loss of $4.04 per share, which came in worse than the analyst consensus estimate of a loss of $1.11 per share. ]
The company reported quarterly sales of $2.72 million, falling short of the analyst consensus estimate of $3.94 million by 31%. However, this figure reflects a slight increase of 1.6% from the $2.68 million in sales reported in the same quarter of the previous year.
The company's Mytesi prescription volume rose by 5.2% from first-quarter 2024, though it saw a slight year-over-year decline. Financially, Jaguar reduced its net loss by $2.6 million to $9.5 million compared to second-quarter 2023.
Operating losses decreased by $0.9 million, and R&amp;D expenses fell by $0.6 million due to the winding down of its OnTarget clinical trial. The company meanwhile plans a commercial launch of its FDA-approved Gelclair in October 2024 and continues to develop treatments for rare diseases.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/08/40338228/starbucks-appoints-chipotle-mexican-grill-veteran-as-new-ceo-stock-soars">Starbucks Appoints Chipotle Mexican Grill Veteran As New CEO, Stock Soars</a>
<h2 class="wp-block-heading">Should I Sell My JAGX Stock?</h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Jaguar Health stock currently has an RSI of 60.97, indicating neutral conditions.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>
JAGX has a 52-week high of $35.34 and a 52-week low of $1.03.

WIIM

Jaguar Health shares are trading lower after the company reported worse-than-expected second-quarter results.

Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) reported quarterly losses of $(4.04) per share which missed the analyst consensus estimate of $(1.11) by 263.96 percent. This is a 861.9 percent decrease over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $2.72 million which missed the analyst consensus estimate of $3.94 million by 30.93 percent. This is a 1.64 percent increase over sales of $2.68 million the same period last year.

Jaguar Health Q2 EPS $(4.04) Misses $(1.11) Estimate, Sales $2.72M Miss $3.94M Estimate

U.S. stocks traded slightly higher toward the end of trading, with the Dow Jones gaining by more than 50 points on Tuesday.
The Dow traded up 0.17% to 40,483.92 while the NASDAQ rose 0.20% to 18,043.64. The S&amp;P 500 also rose, gaining, 0.14% to 5,572.07.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/07/39904913/how-to-earn-500-a-month-from-alphabet-stock-ahead-of-q2-earnings-report">How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 0.5% on Tuesday.
In trading on Tuesday, energy shares fell by 1.4%.
Top Headline
Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) reported better-than-expected second-quarter results and raised its guidance.
The company reported second-quarter FY24 sales growth of 3% year-on-year to $12.4 billion, beating the analyst consensus estimate of $11.753 billion. Adjusted EPS of 84 cents beat the consensus estimate of 81 cents.
Coca-Cola raised its FY24 organic revenue growth outlook from 8% – 9% to 9% – 10%. KO raised comparable currency neutral EPS growth outlook from 11% – 13% to 13% – 15%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares shot up 326% to $6.91 after the company announced that the U.S. Patent and Trademark Office granted it U.S. Patent No. 12,036,248 for the treatment of atopic dermatitis.</li>
<li>Shares of Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) got a boost, surging 39% to $1.47 after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.</li>
<li>Frequency Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) shares were also up, gaining 33% to $13.48 following fourth-quarter earnings. Also, the company declared a $1.00 special cash dividend.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares dropped 57% to $1.84 after the company announced its phase 3 OnTarget trial results for Crofelemer did not meet its primary endpoint.</li>
<li>Shares of TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) were down 62% to $0.30 after the company priced $3 million public offering of 10 million common shares at $0.30 per share.</li>
<li>Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) was down, falling 19% to $2.4502. The company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/07/39905767/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-with-over-3-dividen">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks With Over 3% Dividend Yields </a>
Commodities In commodity news, oil traded down 1.6% to $77.12 while gold traded up 0.5% at $2,407.20.
Silver traded down 0.1% to $29.305 on Tuesday, while copper fell 0.9% to $4.1605.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 climbed 0.13%, Germany's DAX gained 0.82% and France's CAC 40 fell 0.31%. Spain's IBEX 35 Index rose 0.62%, while London's FTSE 100 fell 0.38%.
Asia Pacific Markets
Asian markets closed lower on Tuesday, with Japan's Nikkei 225 falling 0.01%, Hong Kong's Hang Seng Index falling 0.94%, China's Shanghai Composite Index declining 1.65% and India's S&amp;P BSE Sensex declining 0.09%.
The annual inflation rate in Hong Kong rose to 1.5% in June from 1.2% in the prior month. The People&#8217;s Bank of China slashed one-year loan prime rate by 10bps to 3.35%.
Economics
<ul>
<li>The composite manufacturing index in the US Fifth District fell to -17 in July compared to a reading of -10 in June.</li>
<li>Existing home sales declined by 5.4% from the prior month to an annualized rate of 3.89 million units for June.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/07/39906268/this-coinbase-global-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday">This Coinbase Global Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday</a>

Shares of Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) fell sharply during Tuesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/39908857/comcasts-q2-earnings-studios-and-theme-parks-pull-revenue-lower-broadband-and-video-subs-fall">second-quarter sales results</a>.
Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Comcast shares declined 6.1% to $37.12 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office granted it U.S. Patent No. 12,036,248 for the treatment of atopic dermatitis.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) jumped 148% to $2.6299 after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.</li>
<li>Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) gained 111% to $3.2540.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares climbed 67% to $0.2390.</li>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) rose 45% to $2.7950.</li>
<li>Dermata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) gained 43% to $2.41.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) jumped 36.5% to $4.60.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) gained 33.5% to $0.6385 after jumping around 20% on Monday.</li>
<li>Frequency Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) shares climbed 30% to $13.11 following fourth-quarter earnings. Also, the company declared a $1.00 special cash dividend.</li>
<li>Mammoth Energy Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TUSK#NASDAQ">TUSK</a>) gained 26% to $4.42 after the company announced its subsidiary, Cobra Acquisitions, entered into a release and settlement agreement with the Puerto Rico Electric Power Authority.</li>
<li>iClick Interactive Asia Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLK#NASDAQ">ICLK</a>) rose 23.5% to $2.05.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) jumped 19.3% to $2.90.</li>
<li>Milestone Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#NYSE">MLSS</a>) gained 17.5% to $1.02 after the company announced the Medicare price assignment for its CompuFlo Epidural System.</li>
<li>Staffing 360 Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) gained 16% to $2.1493.</li>
<li>Kiniksa Pharmaceuticals International, plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) rose 16% to $24.81 after the company reported better-than-expected second-quarter sales results and raised its FY24 net product revenue guidance.</li>
<li>Aeva Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NYSE">AEVA</a>) gained 15.1% to $3.6713.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) jumped 12.7% to $333.02 following second-quarter earnings.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) gained 11.8% to $12.34.</li>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) rose 11.8% to $6.90.</li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) gained 11.1% to $561.96 following better-than-expected second-quarter financial results.</li>
<li>Crown Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) rose 8.5% to $84.04 after the company reported better-than-expected second-quarter earnings and raised its FY24 EPS guidance above estimates.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) gained 8% to $96.75 following better-than-expected quarterly earnings.</li>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) gained 8% to $16.51 as the company released preliminary second quarter 2024 financial results and signed a definitive agreement to acquire Rotech Healthcare for $1.36 billion in cash.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares surged 8% to $8.15. Mesoblast recently started enrollment in Phase 3 trial of Rexlemestrocel-L for chronic low back pain.</li>
<li>Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) climbed 7.7% to $86.19 after the company reported better-than-expected second quarter financial results and revised its FY24 adjusted EPS guidance above estimates.</li>
<li>Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) gained 7.4% to $269.35 after the company reported better-than-expected second quarter earnings.</li>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) gained 6.4% to $173.21 after the company reported better-than-expected second quarter adjusted EPS and raised its FY24 outlook.</li>
<li>SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) rose 6% to $0.2390 after the company reported second-quarter financial results.</li>
<li>Zions Bancorporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) gained 5.4% to $52.12 after posting better-than-expected quarterly results on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares dipped 65% to $1.50 after the company announced its phase 3 OnTarget trial results for Crofelemer did not meet its primary endpoint.</li>
<li>TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) dipped 62.2% to $0.2999 after the company announced a proposed public offering.</li>
<li>Fly-E Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) tumbled 59.2% to $2.60.</li>
<li>MIRA Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares dipped 50.3% to $2.4636. MIRA Pharmaceuticals shares jumped 627% on Monday after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares fell 38.3% to $3.1851 after surging 228% on Monday.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) dipped 32.4% to $0.0250.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) fell 32.2% to $1.83.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) fell 31.1% to $0.3440.</li>
<li>Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) dipped 26.2% to $2.23. The company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) fell 23% to $0.77.</li>
<li>Castellum, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>) fell 20% to $0.1594. Castellum recently announced a new strategic alliance with Krilla Kaleiwahea.</li>
<li>Netcapital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>) fell 17.3% to $0.0926 after gaining around 8% on Monday.</li>
<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares declined 16.6% to $364.00 after the company reported mixed second-quarter financial results and narrowed its FY24 revenue guidance with its midpoint below estimates.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) dipped 15.2% to $16.48.</li>
<li>United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) fell 13.2% to $126.04 after the company reported worse-than-expected quarterly financial results.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) shares fell 10% to $0.4479 after gaining over 55% on Monday.</li>
<li>NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) shares fell 9.5% to $256.55 following mixed second-quarter earnings.</li>
<li>New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) dipped 9.2% to $23.28.</li>
<li>PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) fell 8.4% to $99.92 after the company reported worse-than-expected second-quarter financial results.</li>
<li>A. O. Smith Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>) declined 8.4% to $81.30. The company reported second-quarter financial results.</li>
<li>WEBTOON Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) dipped 7.7% to $22.00.</li>
<li>Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) declined 7.2% to $76.23 after the company reported worse-than-expected second-quarter financial results and cut its guidance.</li>
<li>Archrock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) shares declined 6.9% to $21.76. Archrock commenced public offering of 11 million shares of its common stock and announced plans to acquire Total Operations and Production Services for $983 million in cash and stock.</li>
<li>General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) fell 6.1% to $46.52 after the company reported second-quarter financial results. Also, the company announced that it delayed its 2024 Buick EV and pushed its EV pickup plant opening to 2026.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39907957/microsoft-to-rally-around-10-here-are-10-top-analyst-forecasts-for-monday">Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares are falling Tuesday after the company announced its phase 3 OnTarget trial results for crofelemer did not meet its primary endpoint.
The Details:
Jaguar Health said the initial results from its OnTarget study for crofelemer show the multicenter, double-blind, placebo-controlled pivotal clinical trial did not meet its primary endpoint for the prespecified analysis of all tumor types in the trial. Crofelemer is an FDA-approved prescription drug for the symptomatic relief of diarrhea in adult HIV/AIDS patients receiving antiretroviral therapy.&nbsp;
"We believe the OnTarget trial, designed boldly to address a broad array of cancer patients undergoing therapy known to be associated with diarrhea, did not meet the primary endpoint given the heterogeneous nature of the patients enrolled in the trial. Nevertheless, we are pleased that our preliminary analysis of the study data shows a clinically meaningful benefit in response to crofelemer in patients with breast and respiratory cancers, including lung cancer," said Lisa Conte, CEO of Jaguar.
Read Next: <a href="https://www.benzinga.com/news/24/07/39891006/sunpower-stock-attempts-to-bounce-back-whats-going-on">SunPower Stock Attempts To Bounce Back: What&#8217;s Going On?</a>
Jaguar shares are dropping on heavy trading volume with more than 7.5 million shares already traded in Tuesday's session. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, the stock has a float of only 4.889 million shares after <a href="https://www.benzinga.com/news/24/05/38990325/whats-going-on-with-jaguar-health-stock">having effected</a> a 1-for-60 reverse split at the end of May.&nbsp;
<h2 class="wp-block-heading">How To Buy JAGX Stock: </h2>
By now you're likely curious about how to participate in the market for Jaguar Health &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of Jaguar Health, which is trading at $1.44 as of publishing time, $100 would buy you 69.44 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
JAGX Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Jaguar Health shares are down 56.2% at $1.87 at the time of publication Tuesday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39891755/whats-going-on-with-coinbase-shares-today">What&#8217;s Going On With Coinbase Shares Today?</a></li>
</ul>
Image: Mediamodifier from Pixabay

Movers

Why Jaguar Health Stock Is Crashing

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday.
The Dow traded up 0.09% to 40,452.70 while the NASDAQ rose 0.62% to 18,119.84. The S&amp;P 500 also rose, gaining, 0.32% to 5,582.32.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/07/39904913/how-to-earn-500-a-month-from-alphabet-stock-ahead-of-q2-earnings-report">How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1% on Tuesday.
In trading on Tuesday, energy shares fell by 1.4%.
Top Headline
GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) reported better-than-expected second-quarter earnings and raised its FY24 outlook.
GE Aerospace reported second-quarter 2024 adjusted revenue growth of 4% year-over-year to $8.22 billion, missing the consensus of $8.462 billion. Adjusted EPS was $1.20 (+61% YoY), beating the consensus of 99 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares shot up 455% to $9.00 after the company announced that the U.S. Patent and Trademark Office granted it U.S. Patent No. 12,036,248 for the treatment of atopic dermatitis.</li>
<li>Shares of Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) got a boost, surging 62% to $1.7150 after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.</li>
<li>Frequency Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) shares were also up, gaining 30% to $13.15 following fourth-quarter earnings. Also, the company declared a $1.00 special cash dividend.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares dropped 64% to $1.5387 after the company announced its phase 3 OnTarget trial results for Crofelemer did not meet its primary endpoint.</li>
<li>Shares of TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) were down 62% to $0.2997 after the company priced $3 million public offering of 10 million common shares at $0.30 per share.</li>
<li>Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) was down, falling 24% to $2.2850. The company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/07/39905767/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-with-over-3-dividen">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks With Over 3% Dividend Yields</a>
Commodities In commodity news, oil traded down 2% to $76.86 while gold traded up 0.4% at $2,405.00.
Silver traded down 0.5% to $29.19 on Tuesday, while copper fell 0.9% to $4.16.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 climbed 0.07%, Germany's DAX gained 0.68% and France's CAC 40 fell 0.33%. Spain's IBEX 35 Index rose 0.57%, while London's FTSE 100 fell 0.43%.
Asia Pacific Markets
Asian markets closed lower on Tuesday, with Japan's Nikkei 225 falling 0.01%, Hong Kong's Hang Seng Index falling 0.94%, China's Shanghai Composite Index declining 1.65% and India's S&amp;P BSE Sensex declining 0.09%.
The annual inflation rate in Hong Kong rose to 1.5% in June from 1.2% in the prior month. The People&#8217;s Bank of China slashed one-year loan prime rate by 10bps to 3.35%.
Economics
The composite manufacturing index in the US Fifth District fell to -17 in July compared to a reading of -10 in June.
Existing home sales declined by 5.4% from the prior month to an annualized rate of 3.89 million units for June.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39906268/this-coinbase-global-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday">This Coinbase Global Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday</a> </li>
</ul>

Crude Oil Down 2%; GE Aerospace Earnings Top Views

U.S. stocks traded slightly higher this morning, with the Nasdaq Composite gaining around 0.2% on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.01% to 40,421.01 while the NASDAQ rose 0.19% to 18,041.10. The S&amp;P 500 also rose, gaining, 0.18% to 5,574.56.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/07/39904913/how-to-earn-500-a-month-from-alphabet-stock-ahead-of-q2-earnings-report">How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 0.8% on Tuesday.
In trading on Tuesday, utilities shares fell by 0.5%.
Top Headline
General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) reported better-than-expected second-quarter earnings and raised its guidance.
General Motors reported a fiscal second-quarter 2024 sales growth of 7.2% year-on-year to $47.97 billion, beating the analyst consensus estimate of $45.30 billion. The adjusted EPS of $3.06 beat the analyst consensus estimate of $2.72.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares shot up 517% to $10.00 after the company announced that the U.S. Patent and Trademark Office granted it U.S. Patent No. 12,036,248 for the treatment of atopic dermatitis.</li>
<li>Shares of Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) got a boost, surging 158% to $2.75 after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares were also up, gaining 65% to $0.2356.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares dropped 66% to $1.4203 after the company announced its phase 3 OnTarget trial results for Crofelemer did not meet its primary endpoint.</li>
<li>Shares of TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) were down 62% to $0.3007 after the company announced a proposed public offering.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) was down, falling 30% to $0.3523.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/07/39905767/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-with-over-3-dividen">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks With Over 3% Dividend Yields</a> 
Commodities In commodity news, oil traded down 0.3% to $78.14 while gold traded up 0.7% at $2,410.80.
Silver traded down 0.1% to $29.295 on Tuesday, while copper fell 0.6% to $4.1740.
Euro zone
European shares were higher today. The eurozone's STOXX 600 climbed 0.6%, Germany's DAX gained 1.3% and France's CAC 40 climbed 0.4%. Spain's IBEX 35 Index rose 0.7%, while London's FTSE 100 rose 0.4%.
Asia Pacific Markets
Asian markets closed lower on Tuesday, with Japan's Nikkei 225 falling 0.01%, Hong Kong's Hang Seng Index falling 0.94%, China's Shanghai Composite Index declining 1.65% and India's S&amp;P BSE Sensex declining 0.09%.
The annual inflation rate in Hong Kong rose to 1.5% in June from 1.2% in the prior month. The People&#8217;s Bank of China slashed one-year loan prime rate by 10bps to 3.35%.
Economics
<ul>
<li>The composite manufacturing index in the US Fifth District fell to -17 in July compared to a reading of -10 in June.</li>
<li>Existing home sales declined by 5.4% from the prior month to an annualized rate of 3.89 million units for June.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39906268/this-coinbase-global-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday">This Coinbase Global Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday</a> </li>
</ul>

US Stocks Edge Higher; General Motors Posts Upbeat Earnings

Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript

Jaguar Health (JAGX) announced that it is seeking a partner to fund and execute the development and commercialization of NP300, the company's presc...

Jaguar Health seeking partner to develop, commercialize NP300

Jaguar Health's (JAGX) Napo Pharmaceuticals announced that the data from the recently conducted analysis of the prespecified subgroup of adult pati...

Jaguar Health to present data on crofelemer for CTD in breast cancer patients

Jaguar Health (JAGX)family company Napo Pharmaceuticals provided an overview of the data from the poster presentation conducted yesterday, December...

Jaguar Health announces results of crofelemer for CTD in breast cancer patients

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

FDA approves orphan-drug designation for Jaguar Health's cholera drug, Crofelemer

Jaguar Health's (JAGX) Napo Pharmaceuticals announced that the U.S. Food and Drug Administration has granted orphan-drug designation to crofelemer,...

Jaguar Health granted Orphan Drug designation for crofelemer for diarrhea

President & CEO Conte and CSO Chaturvedi provide updates on the five clinical efforts: 3 POC investigator-initiated trials and two company Phase II...

Jaguar Health participates in a conference call with Ladenburg Thalmann

Jaguar Health's (JAGX) Napo Pharmaceuticals and Napo Therapeutics announced that Napo's Phase 2 study to evaluate the efficacy of crofelemer, Jagua...

Jaguar Health's Napo initiates Phase 2 study to evaluate crofelemer for MVID

Jaguar Health (JAGX) announced that Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health (FLHLF), completed an import of six...

Jaguar Health announces import of coca leaf by Magdalena Biosciences JV

ANAB

AUPH

BGNE

CMRX

EYEN

QURE

XFOR

Press Releases

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine

U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins

Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)

Comments

Jaguar Health

Jaguar Health (JAGX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga